TipRanks
Go Ultimate55% OFF

Singular Health Group Ltd (SHG) AI Stock Analysis

AU:SHG

Singular Health Group Ltd

(ASX:SHG)

Select Model
Rating:44Neutral
Price Target:AUD 0.19â–¼(-3.00% Downside)
Action:upgraded
Date:11/03/26

The score is primarily constrained by very weak profitability, sustained cash burn, and negative valuation metrics. Positive near-term technical momentum and reduced debt provide partial support, but they do not offset the company’s substantial financial and funding risks.

Positive Factors
Revenue GrowthMeaningful revenue improvement indicates that Singular Health Group is gaining traction for its medical imaging and digital health offerings. If this growth persists, greater scale could improve operating leverage, support product investment, and strengthen the company’s ability to build a sustainable commercial base.
Negative Factors
Persistent UnprofitabilityPersistent operating and net losses, combined with negative gross profit in 2026, show that revenue growth has not yet translated into a viable profit engine. Continued weak margins can restrict reinvestment, erode equity over time, and make the business model dependent on future improvement.

Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)

-50%-40%-30%-20%-10%0%10%20%AU:SHG-27.27%EWA+14.93%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 68.48M
Dividend Yield
―
Average Volume (3M)
276.18K
Price to Earnings (P/E)
-10.3
Beta (1Y)
0.92
Revenue Growth
603.32%
EPS Growth
10.57%
Country
Australia
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Singular Health Group Ltd Business Overview & Revenue Model

Company Description

Singular Health Group Ltd operates as a medical technology enterprise dedicated to developing and commercializing a volumetric rendering platform (VRP). This advanced platform facilitates the three-dimensional and virtual reality presentation of anat...

Singular Health Group Ltd Financial Statement Overview

Summary

Revenue growth and lower debt are positives, but deeply negative profitability, persistent operating and free-cash-flow losses, and reliance on external funding create very high financial risk. The underlying provided scores average below the permitted range, so the component is set to the minimum score of 37.

Income Statement

22Negative

Balance Sheet

46Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue1.43M1.43M557.61K934.07K28.12K54.03K
Gross Profit-4.06M-4.02M-86.22K516.36K-3.58M-2.11M
EBITDA-6.67M-6.69M-6.27M-2.58M-4.52M-5.65M
Net Income-6.34M-6.34M-6.38M-4.92M-5.39M-5.99M
Balance Sheet
Total Assets11.24M11.24M14.21M2.35M3.00M2.14M
Cash, Cash Equivalents and Short-Term Investments10.06M10.06M13.68M1.45M691.51K1.14M
Total Debt109.96K109.96K0218.45K2.51M85.66K
Total Liabilities699.20K699.20K1.11M909.59K2.94M391.50K
Stockholders Equity10.54M10.54M13.10M1.44M61.89K1.75M
Cash Flow
Free Cash Flow-5.45M-5.45M-2.37M-2.51M-2.49M-2.92M
Operating Cash Flow-5.30M-5.30M-2.34M-2.44M-2.46M-2.91M
Investing Cash Flow5.37M5.37M88.14K-3,559-635.21K-17.12K
Financing Cash Flow1.67M1.67M14.48M3.21M2.65M-69.25K

Singular Health Group Ltd Technical Analysis

Technical Analysis SentimentPositive
Last Price0.20

Price Trends

50DMA0.18Positive
100DMA0.19Positive
200DMA0.21Negative

Market Momentum

MACD0.00Negative
RSI64.31Neutral
STOCH96.30Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SHG, the sentiment is Positive. The current price of 0.20 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.18, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 64.31 is Neutral, neither overbought nor oversold. The STOCH value of 96.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:SHG.

Singular Health Group Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:SHG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:RHTAU:RHT69NeutralAUD 35.31M23.1313.72%―42.25%―
AU:ALCAU:ALC63NeutralAUD 148.48M64.702.53%―26.61%41.67%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:BMTAU:BMT45NeutralAUD 21.26M-1.02-58.13%―2.08%-195.31%
AU:SHGAU:SHG44NeutralAUD 58.70M-10.34-57.06%―603.32%10.57%
AU:M7TAU:M7T42NeutralAUD 61.10M-6.71-24.29%―-17.35%-47.29%
AU:AYAAU:AYA40UnderperformAUD 453.27M-16.95-30.04%―<0.01%2.08%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%AU:SHGAU:M7TAU:RHTAU:BMTAU:AYAAU:ALCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:SHG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:SHGSingular Health Group Ltd0.20-0.07-25.93%
AU:M7TMach7 Technologies Ltd.0.25-0.05-18.03%
AU:RHTResonance Health Ltd0.070.0251.02%
AU:BMTBeamtree Holdings Ltd0.07-0.13-64.50%
AU:AYAArtrya Limited2.86-0.55-16.13%
AU:ALCAlcidion Group Limited0.100.0116.67%

Singular Health Group Ltd Corporate Events

Singular Health Secures Florida Medicaid Imaging Deal as U.S. Expansion Builds Momentum

Oct 27, 2026

Singular Health reported solid strategic progress for the September quarter, highlighted by a memorandum of understanding with Florida International University to design and operate a Medicaid-focused medical imaging repository on its 3DICOM platform...

Singular Health sets date and access details for 2026 AGM

Oct 6, 2026

Singular Health Group has announced that its 2026 Annual General Meeting will be held in person at Automic Group&#8217;s offices in Perth on 26 November 2026 at 11:00am AWST, with the Notice of Meeting and Explanatory Memorandum available online via...

Singular Health to Brief Investors on U.S. Imaging Repository Progress

Oct 1, 2026

Singular Health Group Ltd will host an online investor webinar on 8 October 2026, led by managing director Denning Chong and chief operating officer Dr Martina Mariano, to brief shareholders and investors on the company&#8217;s operations. Management...

Singular Health Sets November Date for 2026 AGM and Opens Director Nominations

Sep 30, 2026

Singular Health Group Ltd has issued advance notice that its 2026 Annual General Meeting is expected to be held around Thursday 26 November 2026, with full meeting details and resolutions to be circulated in a formal Notice of Meeting and Explanatory...

Singular Health Secures Florida Medicaid Imaging Repository Deal With FIU

Sep 28, 2026

Singular Health Group has signed an amended memorandum of understanding with Florida International University to design, deliver and operate a secure medical imaging data repository for Florida&#8217;s Medicaid program using its 3DICOM platform. The...

Singular Health Lodges ASX Corporate Governance Statement and Appendix 4G

Aug 30, 2026

Singular Health Group Ltd, an ASX-listed entity, has detailed its governance framework for the year ended 30 June 2026, including a board charter, appointment processes for directors and senior executives, and the company secretary&#8217;s direct acc...

Singular Health boosts revenue and expands globally despite ongoing losses

Aug 30, 2026

Singular Health Group Limited reported a sharp increase in revenues from ordinary activities to $1.43 million for the year ended 30 June 2026, up 507% from the prior year, while its loss after tax narrowed slightly to $6.34 million. Net tangible asse...

Singular Health Group Seeks ASX Quotation for 1.8 Million New Shares

Aug 17, 2026

Singular Health Group Ltd has applied for quotation on the ASX of 1,818,182 ordinary fully paid shares, with an issue date of 17 August 2026. The new share quotation expands the company&#8217;s listed equity base, potentially enhancing liquidity for...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026